Preferred Networks

Preferred Networks has demonstrated the ability of its AI-driven technologies to accelerate lead compound identification for COVID‑19 therapeutics, develop early diagnostic tools using omics data for diseases like breast cancer and Parkinson’s disease, and improve medical imaging diagnostics. The company collaborates with major pharmaceutical companies such as Chugai Pharmaceutical and academic institutions including Kyoto Pharmaceutical University. Clinical results include successful identification of multiple COVID‑19 lead compounds and promising machine learning models for early detection of breast cancer via blood miRNA.